Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06410924 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH
A Phase 2 study of NAFLD and NASH, sponsored by Neuraly.
- Active
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
- 12
- Study locations
NCT06410924 is a Phase 2 study of NAFLD and NASH that is active but no longer recruiting, run by Neuraly. The registered enrollment target is 67 participants, below the 163-participant average among 26 other NAFLD trials with a reported enrollment target (59% lower). The trial reports 12 study locations across 4 states.
The verdict
NCT06410924, a Phase 2 study of NAFLD and NASH, is active but no longer recruiting, sponsored by Neuraly.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a Phase 2 Study to evaluate the effect of DD01 treatment in overweight/obese patients with metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH).
Interventions
- DRUG Placebo
- DRUG DD01
Study Locations (12)
Texas
- Summit Research Site - Austin
- Summit Research Site - Bellaire
- Summit Research Site - Brownsville
- Summit Research Site - Corpus Christi
- Summit Research Site - Edinburg
- Summit Research Site - Georgetown
- Summit Research Site - San Antonio
- Summit Research Site - San Antonio
Louisiana
- Summit Research Site - Monroe
- Summit Research Site - West Monroe
Florida
- Summit Research Site - Maitland
Missouri
- Summit Research Site - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2024-06-13 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06410924
The ClinicalTrials.gov registry entry for NCT06410924 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 163-participant average among 26 other NAFLD trials with a reported enrollment target (59% lower). The listed sponsor is Neuraly, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with NAFLD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06410924 reports 12 study locations spanning 4 distinct geographic areas - top geographies include Texas, Louisiana, Florida.
Frequently Asked Questions
What is clinical trial NCT06410924 about?
NCT06410924 is a clinical study titled "A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH". This is a Phase 2 Study to evaluate the effect of DD01 treatment in overweight/obese patients with metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH).
What is the current status of trial NCT06410924?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2024-06-13. Estimated completion is 2026-06.
What conditions does trial NCT06410924 study?
This clinical trial studies the following conditions: NAFLD, NASH.
What interventions are being tested in trial NCT06410924?
The interventions under investigation include: Placebo (DRUG), DD01 (DRUG).
Who is sponsoring clinical trial NCT06410924?
This trial is sponsored by Neuraly, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06410924 being conducted?
This trial has 12 study locations across Florida, Louisiana, Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NAFLD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
RECRUITING · Phase 2
-
Digoxin In NASH (CODIN)
RECRUITING · Phase 2
-
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
ACTIVE NOT RECRUITING · Phase 2
-
Treating PCOS With Semaglutide vs Active Lifestyle Intervention
COMPLETED · Phase 2
-
Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.